RED GUIDELINE

1
Progress on new vaccines introduction in the AFRO
Region
Dr Tarande ManzilaAFRO/ Regional Office

2
AFRO Regional goals for new vaccine introduction

• By 2005
• All countries in the region will have been
  assisted for the integration of hepatitis B
  vaccine in their routine EPI programmes
• In which ever country that will introduce Hep B
  vaccine coverage of the newly introduced Hep B
  will at least be equal to DTP3
• At least half of the countries with Hep B vaccine
  will be assisted for the integration of
  Haemophilus influenzae type b vaccine

3
GAVI ELIGIBLE COUNTRIES
4
Basic eligibility
Basic Conditions GNP/capita lt US 1000 ICC or
equivalent Immunization assessment in last 3
years Multi-year plan for immunization
5
Current status

• Hep B introduction 21/36 countries have
  introduced Hep B in the following presentations
• DTP-HepB Hib (7 countries)
• DTP- Hep B (10 countries)
• Hep B monovalent (4 countries)

Note 36 / 46 countries in the region are GAVI
eligibles
6
Current status

• Hib introduction 11/36 countries have
  introduced Hib in the following presentations
• DTP-HepB Hib (7 countries)
• DTP- Hib (4 countries)
• Hib monovalent ( 0 country)

7
Current status

• Regional discrepancies Eastern Block
• Hep B All countries (7 countries)
• Hib 4/7 countries
• Southern Block
• Hep B All countries (Not Namibia)
• Hib 3/14 countries

8
Current status

• Regional discrepancies Central Block
• Hep B 2/7 countries
• Hib 0/7 countries
• Western Block
• Hep B 4/16 countries
• Hib 2(2)/16 countries

9
Progress on new vaccines introdruction in AFRO

2000
2001
-
2003




Hep B

Hib

Fièvre Jaune

10
10
11
Yellow Fever vaccine
Yellow fever vaccine has been incorporated into
EPI in 19 out of the 31 countries at risk in the
WHO African Region. as of March 2004
YF vaccine integrated into EPI YF vaccine
integrated into EPI with GAVI support
12
Conclusion

• No interest in Hib alone
• Hib integrated as a added value of combination
  vaccine presentations
• Remaining countries have to yet increase DTP3
  coverage before integrating New vaccines
• New vaccine introduction can significantly
  increase EPI programmes cost
• Sustaining delivery after the GAVI/VF support
  period